CLINICAL TRIAL, CROSS, RANDOMIZED, DOUBLE BLIND, CONTROLLED AGAINST PLACEBO USING VALACICLOVIR TO REMOVE THE EXCRETION OF SIMPLE HERP VIRUS (VHS) AND HUMAN IMMUNODEFICIENCY VIRUSES (HIV) IN INDIVIDUALS COINFECTED WITH HIV TYPE 1 AND VHS TYPE 2.
Not Applicable
- Conditions
- -B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24
- Registration Number
- PER-082-02
- Lead Sponsor
- GLAXOSMITHKLINE RESEARCH TRIANGLE PARK,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
• Be over 18 years of age.
• Be documented HIV-1 positive.
• Have a CD4 count greater than 200.
• Not receiving antiretroviral therapy for HIV.
• Be positive VHS-2 determined by the EIA test (IN> 3.5).
• Do not intend to travel or emigrate during the time the study lasts.
Exclusion Criteria
■ Known history of adverse reactions to valacyclovir, aciclovir or famciciovir.
■ Plan the open use of Aciclovir, valaciclovir, or famciciovir.
■ History of seizures.
■ Renal insufficiency or serum creatinine> 2.0 mg / dl.
■ Hematocrit less than 30%.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method